Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of April 2019 for Enlivex Therapeutics Ltd., an Israeli company. The filing discloses a material corporate event: a private placement of ordinary shares completed in early April 2019.
Key Financial Metrics
The filing details a capital raise but does not provide comprehensive financial statements such as revenue, profit, cash flow, or debt levels for the period.
- Gross Proceeds: Approximately $3.0 million.
- Shares Issued: 244,898 ordinary shares.
- Purchase Price: $12.25 per share.
- Transaction Date: April 4, 2019 (Agreement signed April 3, 2019).
Material Changes
The primary material change is the increase in equity capital resulting from the private placement. The shares were sold to a private investor under exemptions from registration (Section 4(a)(2) of the Securities Act and/or Regulation S). No other material changes to operations or financial position are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond standard legal disclaimers. It explicitly states that the report does not constitute an offer to sell securities and notes that the shares issued were not registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing of the $3.0 million private placement and the use of proceeds.
- Confirm the total number of outstanding shares post-issuance to assess dilution impact.
- Review subsequent filings for any registration statements (e.g., Form S-8) referenced in this document.
- Check for any additional capital raises or material agreements in the weeks following April 2019.